• 00:00 1.
    index 1
  • 00:32 2.
    Cyclin E1 and CDK4/6
  • 00:32 3.
    Palbociclib , CDK4/6 inhibitor
  • 00:32 4.
    Cyclin E1 and CDK4/6
  • 00:33 5.
    Slide 1
  • 00:33 6.
    Cyclin E1 and CDK4/6
  • 01:19 7.
    Palbociclib , CDK4/6 inhibitor
  • 01:22 8.
    Cyclin E1 and CDK4/6
  • 04:27 9.
    Palbociclib , CDK4/6 inhibitor
  • 05:50 10.
    Cyclin E1 and CDK4/6
  • 05:58 11.
    Palbociclib , CDK4/6 inhibitor
  • 07:14 12.
    Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
  • 07:16 13.
    Palbociclib , CDK4/6 inhibitor
  • 09:44 14.
    Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
  • 09:57 15.
    Palbociclib , CDK4/6 inhibitor
  • 10:25 16.
    Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
  • 15:20 17.
    Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
  • 28:48 18.
    EILA predicts poor prognosis in breast cancer patients
  • 40:12 19.
    EILA predicts poor prognosis in breast cancer patients
  • 51:41 20.
    EILA is required for CDK4/6 inhibitor resistance
  • 54:11 21.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 54:12 22.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 54:16 23.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 54:19 24.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 54:19 25.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 54:19 26.
    EILA is required for CDK4/6 inhibitor resistance
  • 54:20 27.
    EILA predicts poor prognosis in breast cancer patients
  • 54:21 28.
    EILA predicts poor prognosis in breast cancer patients
  • 54:21 29.
    EILA predicts poor prognosis in breast cancer patients
  • 54:22 30.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:00:54 31.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:01:47 32.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:02:13 33.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:14 34.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:02:24 35.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:25 36.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:02:27 37.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:28 38.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:02:30 39.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:30 40.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:02:31 41.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:32 42.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:02:33 43.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:34 44.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:02:36 45.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:36 46.
    EILA is required for CDK4/6 inhibitor resistance
  • 1:02:43 47.
    Cellular Senescence Detection Kit - SPiDER-βGal
  • 1:02:44 48.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:02:48 49.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:02:49 50.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:05:14 51.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:11:46 52.
    EILA hinders the ubiquitination-mediated degradation of cyclin E1
  • 1:11:49 53.
    Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
  • 1:12:03 54.
    EILA hinders the ubiquitination-mediated degradation of cyclin E1
  • 1:15:14 55.
    EILA hinders the ubiquitination-mediated degradation of cyclin E1
  • 1:18:05 56.
    EILA expression is regulated by CTCF/CDK8/TFII-I complexes
  • 1:22:36 57.
    EILA expression is regulated by CTCF/CDK8/TFII-I complexes
  • 1:26:05 58.
    EILA promotes CDK4/6 inhibitor resistance in vivo
  • 1:27:10 59.
    EILA promotes CDK4/6 inhibitor resistance in vivo
  • 1:28:15 60.
    EILA predicts poor response to CDK4/6i treatment
  • 1:29:27 61.
    Slide 19
  • 1:29:28 62.
    EILA predicts poor response to CDK4/6i treatment
  • 索引
  • 筆記
  • 討論
  • 全螢幕
20241216 lab meeting_楷軒
長度: 1:32:32, 瀏覽: 66, 最近修訂: 2024-12-16
    下一篇
    • 00:00 1.
      index 1
    • 00:32 2.
      Cyclin E1 and CDK4/6
    • 00:32 3.
      Palbociclib , CDK4/6 inhibitor
    • 00:32 4.
      Cyclin E1 and CDK4/6
    • 00:33 5.
      Slide 1
    • 00:33 6.
      Cyclin E1 and CDK4/6
    • 01:19 7.
      Palbociclib , CDK4/6 inhibitor
    • 01:22 8.
      Cyclin E1 and CDK4/6
    • 04:27 9.
      Palbociclib , CDK4/6 inhibitor
    • 05:50 10.
      Cyclin E1 and CDK4/6
    • 05:58 11.
      Palbociclib , CDK4/6 inhibitor
    • 07:14 12.
      Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
    • 07:16 13.
      Palbociclib , CDK4/6 inhibitor
    • 09:44 14.
      Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
    • 09:57 15.
      Palbociclib , CDK4/6 inhibitor
    • 10:25 16.
      Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
    • 15:20 17.
      Cyclin E1 dysregulation promotes CDK4/6 inhibitor resistance
    • 28:48 18.
      EILA predicts poor prognosis in breast cancer patients
    • 40:12 19.
      EILA predicts poor prognosis in breast cancer patients
    • 51:41 20.
      EILA is required for CDK4/6 inhibitor resistance
    • 54:11 21.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 54:12 22.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 54:16 23.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 54:19 24.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 54:19 25.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 54:19 26.
      EILA is required for CDK4/6 inhibitor resistance
    • 54:20 27.
      EILA predicts poor prognosis in breast cancer patients
    • 54:21 28.
      EILA predicts poor prognosis in breast cancer patients
    • 54:21 29.
      EILA predicts poor prognosis in breast cancer patients
    • 54:22 30.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:00:54 31.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:01:47 32.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:02:13 33.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:14 34.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:02:24 35.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:25 36.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:02:27 37.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:28 38.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:02:30 39.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:30 40.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:02:31 41.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:32 42.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:02:33 43.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:34 44.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:02:36 45.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:36 46.
      EILA is required for CDK4/6 inhibitor resistance
    • 1:02:43 47.
      Cellular Senescence Detection Kit - SPiDER-βGal
    • 1:02:44 48.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:02:48 49.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:02:49 50.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:05:14 51.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:11:46 52.
      EILA hinders the ubiquitination-mediated degradation of cyclin E1
    • 1:11:49 53.
      Hairpin A of EILA stabilizes cyclin E1 protein by its C-terminal domain
    • 1:12:03 54.
      EILA hinders the ubiquitination-mediated degradation of cyclin E1
    • 1:15:14 55.
      EILA hinders the ubiquitination-mediated degradation of cyclin E1
    • 1:18:05 56.
      EILA expression is regulated by CTCF/CDK8/TFII-I complexes
    • 1:22:36 57.
      EILA expression is regulated by CTCF/CDK8/TFII-I complexes
    • 1:26:05 58.
      EILA promotes CDK4/6 inhibitor resistance in vivo
    • 1:27:10 59.
      EILA promotes CDK4/6 inhibitor resistance in vivo
    • 1:28:15 60.
      EILA predicts poor response to CDK4/6i treatment
    • 1:29:27 61.
      Slide 19
    • 1:29:28 62.
      EILA predicts poor response to CDK4/6i treatment
    位置
    1. 知識庫
    2. ...
    3. 2024
    資料夾名稱
    2024
    發表人
    黃鈺涵
    單位
    賴亮全教授
    建立
    2024-12-16 11:15:24
    最近修訂
    2024-12-16 13:36:19
    長度
    1:32:32

    臺北市仁愛路一段1號10樓1009室

    R1009 10F No1 Sec1 Ren-Ai Rd, Taipei 100233, Taiwan.

    E-mail: llai@ntu.edu.tw

    Tel: 886-2-2312-3456 # 288241

    Lab: 886-2-2393-8235